A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
Year: 2013
Type: article
Abstract: Multiple myeloma (MM) is characterized by complex genetic abnormalities whose complexity signifies varying degree of chromosomal instability (CIN). In this study, we introduced a novel CIN measure, chromosome instability genome event count (CINGEC), which considered both copy number aberrations and interstitial breakpoints from high-resolution genome-wide assays. When assessed in two aCGH MM datasets, higher CINGEC was associated with poor survival. We then derived a CINGEC-associated gene expression profile (GEP) signature, CINGECS, using a dataset that has both aCGH and GEP. Genes in CINGECS were mainly involved in DNA damage responses besides in aneuploidy and other generic oncogenic processes contrary to other CIN associated GEP signatures. Finally, we confirmed its survival association in three GEP datasets that encompassed newly diagnosed patients treated with transplant-based protocol with or without novel agents for induction as well as relapsed patients treated with bortezomib. Furthermore, CINGECS was independent of many GEP-based prognostic signatures. In conclusion, our novel CIN measure has definite biological and clinical significance in myeloma.
Source: PLoS ONE
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Damon Runyon Cancer Research Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Celgene, Mayo Foundation for Medical Education and Research, National Research Foundation, National Research Foundation Singapore, Takeda Oncology, National Medical Research Council, National Cancer Institute
OpenAlex ID: W2027337327
